News & Press Releases
Filter by:
How Year-End Attorney Reviews Might Look a Little Different This Year
November 23, 2020
In The American Lawyer, Mintz's Managing Member Bob Bodian addressed the firm's plan to move forward with its traditional fiscal year-end review in March, as well as steady workflow for Associates, despite the pandemic.
Trump Unveils Disputed, Long-Shot Drug Rules Upending System
November 23, 2020
In an article published by Bloomberg Law, Mintz Member Theresa C. Carnegie was quoted on the Trump administration’s proposed foreign drug pricing rule and potential legal challenges from the pharmaceutical industry.
Drug Intermediaries Threaten Lawsuits to Preserve Cut of Prices
November 23, 2020
In an article published by Bloomberg Law, Mintz Member Tara E. Dwyer was quoted on the Trump administration’s proposed final rule, which is currently under review by the Office of Management and Budget, that would end legal shields for drug rebates.
What You Need To Know About the Moderna and Pfizer Coronavirus Vaccines
November 19, 2020
In an article published by The Washington Post, Mintz Member Jennifer B. Rubin was quoted on the potential legal and political issues associated with employers mandating a COVID-19 vaccine once it’s approved by the U.S. Food and Drug Administration.
Myths and Realities About Trump’s Executive Order on Race, Gender
November 19, 2020
Mintz Member, Co-chair of the firm’s Sports & Entertainment Practice, and Chair of the firm’s Diversity Committee Tyrone Thomas authored an article published by Bloomberg Law examining some myths and realities of President Trump’s executive order addressing race and gender references within diversity and inclusion trainings by federal contractors and entities receiving federal grants.
In Growing Trend, Companies Being Whipsawed by Regulators and Courts
November 19, 2020
In the third edition of Stericycle’s 2020 Recall Index, Mintz Member and Co-chair of the firm’s Product Liability Practice Daniel J. Herling authored an article examining a new wave of legal challenges facing consumer product companies related to recall programs negotiated with the U.S. Consumer Product Safety Commission.